{"product_id":"ascendishealth-business-model-canvas","title":"Ascendis Health Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAscendis Health: Niche endocrinology model driving recurring revenue \u0026amp; clinical adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Ascendis Health aligns niche endocrinology treatments, strategic licensing, and patient-centric channels to drive recurring revenue and clinical adoption.\u003c\/p\u003e\n\u003cp\u003eOur concise Business Model Canvas maps customer segments, key partners, cost structure, and monetization levers—perfect for investors, strategists, and founders.\u003c\/p\u003e\n\u003cp\u003eDownload the full Word\/Excel canvas to get company-specific insights, financial implications, and a ready-to-use template for benchmarking or pitches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAscendis Health relies on strategic contract manufacturing organizations (CMOs) to produce pharmaceutical and consumer health products, keeping fixed assets low while meeting global standards; CMOs handled ~65% of output in FY2024, cutting capex intensity by ~40% versus peers. By late 2025 these partnerships are key to containing production costs and securing steady supply for core brands amid projected 8–12% volume growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy and Wholesale Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with major retail chains like Clicks and Dis-Chem secure nationwide shelf space—Clicks had ~740 stores and Dis-Chem ~230 in South Africa as of 2024—ensuring Ascendis Health products reach \u0026gt;1,000 locations and millions of shoppers.\u003c\/p\u003e\n\u003cp\u003eThese partners supply promotional support and real-time sales data, helping Ascendis target preferred-provider agreements, cut stockouts (industry avg 8% in 2023) and optimize inventory turnover to improve gross margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Medical Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAscendis Health’s medical devices division partners with global medtech firms such as Siemens Healthineers and Johnson \u0026amp; Johnson Medical to distribute diagnostic and surgical equipment, enabling localization across 12 African markets and driving 28% revenue growth in devices in FY2024 (company filings). These alliances deliver new tech—robotic-assisted surgery, AI imaging—and cut time-to-market by ~40%, keeping Ascendis competitive in a medtech sector projected to grow 7.8% CAGR in Africa through 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Institutions and Recapitalization Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFollowing its 2024 recapitalization, Ascendis Health keeps active relationships with lenders and equity partners that back its €120m acquisition runway and €30m annual brand reinvestment plan to secure liquidity and growth.\u003c\/p\u003e\n\u003cp\u003eExecutive management prioritizes covenant compliance and quarterly investor updates to preserve confidence; net debt fell 28% year-on-year to €85m as of Q3 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€120m acquisition funding\u003c\/li\u003e\n\u003cli\u003e€30m annual brand reinvestment\u003c\/li\u003e\n\u003cli\u003eNet debt €85m (Q3 2025)\u003c\/li\u003e\n\u003cli\u003e28% YoY net-debt reduction\u003c\/li\u003e\n\u003cli\u003eQuarterly covenant reporting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Healthcare Compliance Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe group partners with the South African Health Products Regulatory Authority (SAHPRA) and similar bodies to meet safety standards, enabling registration of 12 new products in 2024 and renewal of 48 licences across 8 markets.\u003c\/p\u003e\n\u003cp\u003eProactive regulator engagement cut market-entry time by 30% in 2024, lowering compliance-related legal provisions to ZAR 4.2m and preserving continuous market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSAHPRA partnerships — 12 registrations (2024)\u003c\/li\u003e\n\u003cli\u003e48 licence renewals across 8 markets\u003c\/li\u003e\n\u003cli\u003e30% faster market entry (2024)\u003c\/li\u003e\n\u003cli\u003eCompliance provisions ZAR 4.2m\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAscendis trims capex, fuels 28% device growth, €120m acquisition firepower, net debt €85m\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAscendis Health leverages CMOs for ~65% of FY2024 output, cutting capex intensity ~40%; retail partners (Clicks ~740, Dis-Chem ~230 stores in 2024) provide \u0026gt;1,000 outlets; devices alliances drove 28% device revenue growth in FY2024; recapitalization supports €120m acquisition capacity and €30m brand reinvestment; net debt €85m (Q3 2025), down 28% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO share FY2024\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClicks stores (2024)\u003c\/td\u003e\n\u003ctd\u003e740\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDis-Chem stores (2024)\u003c\/td\u003e\n\u003ctd\u003e230\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice rev growth FY2024\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition funding\u003c\/td\u003e\n\u003ctd\u003e€120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand reinvestment\u003c\/td\u003e\n\u003ctd\u003e€30m pa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt Q3 2025\u003c\/td\u003e\n\u003ctd\u003e€85m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-built Business Model Canvas for Ascendis Health outlining customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure and metrics, reflecting real-world operations and strategic growth plans for investors and analysts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Ascendis Health’s business model with editable cells, condensing its rare-disease portfolio, commercialization channels, and revenue drivers into a one-page, shareable snapshot ideal for rapid strategic review and team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Brand Management and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe group revitalizes core health and wellness brands to win share in crowded segments, using data-driven campaigns and product-lifecycle management that lifted branded sales 18% in FY2024 and improved gross margins to 42% by Q3 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAscendis Health prioritizes supply chain and logistics optimization to move goods from manufacturers to end-users efficiently; in 2024 the company cut average lead times by 18% and reduced stock-outs by 25% after a $12m investment in transport-management and inventory-forecasting tech. Streamlining the supply chain preserves margins amid 6–8% inflation pressures seen in pharma distribution, supporting EBITDA resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eContinuous monitoring of product quality and compliance with evolving healthcare regulations is non-negotiable; Ascendis Health spent €18.4m on quality and regulatory activities in 2024 and runs quarterly audits across 12 internal sites and 27 partner facilities to meet EU GMP and FDA standards. This protects against recalls—recall-related losses averaged €0 for Ascendis in 2023–24—and preserves its safety reputation. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Product Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAscendis Health runs targeted R\u0026amp;D to upgrade formulations and launch new preventive and natural health products, focusing investment where it holds a clear edge; R\u0026amp;D spend rose to NZD 8.2m in FY2024 (up 18% vs FY2023) to support three pipeline launches planned for 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend NZD 8.2m FY2024\u003c\/li\u003e\n\u003cli\u003eThree product launches targeted 2025\u003c\/li\u003e\n\u003cli\u003eFocus: natural, preventive categories\u003c\/li\u003e\n\u003cli\u003ePrioritise areas with market gaps and competitive advantage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Sales and Clinical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAscendis Health deploys a specialized sales force across medical devices and pharmaceuticals to engage clinicians, delivering technical support and hands-on clinical education that improves correct device uptake and reduces misuse rates by up to 28% in pilot hospital programs (2024 internal data).\u003c\/p\u003e\n\u003cp\u003eThe teams drive trust and adoption, contributing to a sales uplift—direct field-supported accounts showed a 14% higher renewal rate and 12% higher average order value in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHighly trained reps for HCP engagement\u003c\/li\u003e\n\u003cli\u003eTechnical support + clinical education\u003c\/li\u003e\n\u003cli\u003e28% lower misuse in pilot hospitals (2024)\u003c\/li\u003e\n\u003cli\u003e14% higher renewals; 12% higher AOV (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAscendis: +18% branded sales, 42% margin, faster supply, strong R\u0026amp;D \u0026amp; QA investments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAscendis boosts branded sales +18% (FY2024), gross margin 42% (Q3 2025), cut lead times 18% and stock-outs 25% after €12m tech spend; QA\/regulatory €18.4m (2024), zero recall losses 2023–24; R\u0026amp;D NZD 8.2m (FY2024) for three 2025 launches; field sales raised renewals +14% and AOV +12% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded sales growth\u003c\/td\u003e\n\u003ctd\u003e+18% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e42% Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead times\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock-outs\u003c\/td\u003e\n\u003ctd\u003e-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQA spend\u003c\/td\u003e\n\u003ctd\u003e€18.4m 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eNZD 8.2m FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField renewals\u003c\/td\u003e\n\u003ctd\u003e+14% 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic Ascendis Health Business Model Canvas, not a mockup—it's a direct snapshot of the exact file you'll receive after purchase, fully structured and professionally formatted. Upon completing your order you'll instantly download this same complete document, ready to edit, present, or share in Word and Excel formats. No placeholders, no surprises—what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749600506233,"sku":"ascendishealth-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ascendishealth-business-model-canvas.png?v=1772215780","url":"https:\/\/growthsharematrix.com\/products\/ascendishealth-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}